MULTITARGA LLC

Biotech · Private

Host-Pathogen Enrichment Platform (HostPathEP): software that designs synthetic multi-targeted RNA sequencing reagents optimized for detecting low-abundance pathogen transcripts in host-pathogen sampl

Grants
$305K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Adaptive Multi-Targeted Priming for Host-Pathogen Transcriptomics: Leveraging Graph Representation Learning for High-Resolution Pathogenesis and Immune Profiling$304,995
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3214Artios Pharma——
3215HAWA THERAPEUTICS LLC——
3216Poplar Therapeutics——
3217MULTITARGA LLC——
3218Shield Pharma LLC——
3219QWIXEL THERAPEUTICS, LLC——
3220TARGAZYME, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.